Valuation: Bio-Techne Corporation

Capitalization 6.78B 5.83B 5.33B 5.09B 9.33B 650B 9.48B 63.99B 24.76B 309B 25.44B 24.9B 1,076B P/E ratio 2026 *
37.1x
P/E ratio 2027 * 31.3x
Enterprise value 6.71B 5.77B 5.28B 5.04B 9.23B 644B 9.39B 63.33B 24.51B 306B 25.18B 24.64B 1,065B EV / Sales 2026 *
5.55x
EV / Sales 2027 * 5.07x
Free-Float
99.7%
Yield 2026 *
0.74%
Yield 2027 * 0.74%
1 day-3.22%
1 week-10.46%
Current month-21.73%
1 month-25.97%
3 months-27.75%
6 months-27.08%
Current year-26.37%
1 week 43.2
Extreme 43.195
49.52
1 month 43.2
Extreme 43.195
62.47
Current year 43.2
Extreme 43.195
72.16
1 year 43.2
Extreme 43.195
72.16
3 years 43.2
Extreme 43.195
89.91
5 years 43.2
Extreme 43.195
135.96
10 years 23.92
Extreme 23.92
135.96
Manager TitleAgeSince
Chief Executive Officer 59 01/02/2024
Director of Finance/CFO 55 01/04/2014
Chief Tech/Sci/R&D Officer - 06/08/2023
Director TitleAgeSince
Chairman 70 02/11/2012
Director/Board Member 56 19/05/2009
Director/Board Member 63 26/10/2017
Change 5d. change 1-year change 3-years change Capi.($)
-3.22%-10.46%-10.24%-46.60% 6.78B
-1.01%-2.82%-17.13%-19.68% 41.67B
-3.73%-6.04%+29.90%+22.07% 32.6B
-2.55%+2.71%+269.32%+448.83% 30.97B
-0.91%-5.37%+20.43%-11.67% 28.23B
-3.23%-4.84%+27.92%+22.28% 26.41B
-2.03%+0.77% - - 14.94B
+6.21%-2.39%+170.16%+4,385.95% 14.13B
-1.92%-1.95%+125.01%+104.83% 12.27B
-0.20%-0.10%+6.70%-2.02% 12.12B
Average -1.26%-2.70%+69.12%+544.89% 22.01B
Weighted average by Cap. -1.56%-2.43%+67.58%+375.22%

Financials

2026 *2027 *
Net sales 1.21B 1.04B 951M 908M 1.66B 116B 1.69B 11.41B 4.42B 55.07B 4.54B 4.44B 192B 1.27B 1.09B 997M 951M 1.74B 122B 1.77B 11.96B 4.63B 57.69B 4.75B 4.65B 201B
Net income 184M 159M 145M 138M 254M 17.69B 258M 1.74B 674M 8.4B 692M 677M 29.26B 220M 189M 173M 165M 303M 21.12B 308M 2.08B 804M 10.02B 826M 808M 34.92B
Net Debt -70.15M -60.37M -55.2M -52.66M -96.54M -6.73B -98.14M -662M -256M -3.2B -263M -258M -11.13B -358M -308M -282M -269M -493M -34.36B -501M -3.38B -1.31B -16.31B -1.34B -1.32B -56.83B
Logo Bio-Techne Corporation
Bio-Techne Corporation specializes in the manufacture and marketing of products used in life science research. The group offers reagents and diagnostic tools for researchers, doctors, laboratories, pharmaceutical and biotechnology companies, etc. Net sales break down by family of products as follows: - biological and chemical reagents and analysis tools (71.3%): proteins, antibodies, molecules, culture serums, tools for cell work, tools for the study of proteins, immunoassay tools, etc.; - diagnostic and genomics products (28.4%): reagents and products used in blood analysis, nucleic acid analysis, tissue biopsy, gene analysis, cancer and genetic carrier screening, etc. ; - other (0.3%). Net sales are distributed geographically as follows: the United States (56%), the United Kingdom (4.5%), Europe/Middle East/Africa (21.8%), China (8.3%), Asia/Pacific (6.3%) and other (3.1%).
Employees
3,100
Date Price Change Volume
15/05/26 43.30 $ -3.22% 5,229,694
14/05/26 44.74 $ -0.33% 3,425,809
13/05/26 44.89 $ -5.34% 3,904,911
12/05/26 47.42 $ 0.00% 1,767,193
11/05/26 47.42 $ -1.94% 2,706,682
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
43.30USD
Average target price
62.58USD
Spread / Average Target
+44.53%

Quarterly revenue - Rate of surprise